ArticleCase reports in hepatology2026
Ashwagandha-Induced Herb-Induced Liver Injury Assessed With the Updated 2016 RUCAM.
Article in Case reports in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ashwagandha-Induced Herb-Induced Liver Injury Assessed With the Updated 2016 RUCAM.Case reports in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ashwagandha-induced herb-induced liver injury (HILI) has increasingly been reported; however, many published cases show methodological variability in causality assessment and limited clinicopathological correlation. We present a case of ashwagandha-associated liver injury with systematic causality evaluation using the updated 2016 Roussel Uclaf Causality Assessment Method (RUCAM) and comprehensive clinicopathological correlation. A previously healthy 27-year-old woman developed jaundice and generalized pruritus after consuming ashwagandha for three days. Infectious, autoimmune, and metabolic etiologies were excluded. Abdominal magnetic resonance imaging showed no structural abnormalities, while liver biopsy demonstrated a classic cholestatic pattern without fibrosis. Causality assessment using the updated 2016 RUCAM yielded a score of 7 points, consistent with probable HILI. The patient received symptomatic management, corticosteroids, and azathioprine, with progressive clinical and biochemical improvement. This case highlights the value of a systematic causality approach using updated RUCAM criteria together with complete clinicopathological correlation to strengthen diagnostic confidence in suspected HILI associated with herbal supplements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.